11.08.17
EyeGate Completes Enrollment in Phase 2b Clinical Trial of EGP-437 for Cataract Surgery
Triggers Milestone Payment under Global Licensing Agreement with Valeant Pharmaceuticals WALTHAM, Mass., Nov. 08, 2017 -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with...
Read more